References
- Bahadur N, Leathart JB, Mutch E, et al. (2002). CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64:1579–89
- Baldwin SJ, Bloomer JC, Smith GJ, et al. (1995). Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261–70
- Chen C, Wei X, Rao X, et al. (2011). Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. J Pharmacol Exp Ther 336:344–55
- Jiang JG, Chen CL, Card JW, et al. (2005). Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65:4707–15
- Jiang JG, Fu XN, Chen CL, et al. (2009). Expression of cytochrome P450 arachidonic acid epoxygenase 2J2 in human tumor tissues and cell lines. Ai Zheng 28:93–6
- Kim MJ, Kim H, Cha IJ, et al. (2005). High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651–8
- Lee B, Kang W, Shon JC, et al. (2014a). Potential of 4′-(p-Toluenesulfonylamide)-4-hydroxychalcone to inhibit the human cytochrome P450 2J2 isoform. J Korean Soc Appl Biol Chem 57:31–4
- Lee B, Wu Z, Sung SH, et al. (2014b). Potential of decursin to inhibit the human cytochrome P450 2J2 isoform. Food Chem Toxicol 70:94–9
- Lee CR, Pieper JA, Frye RF, et al. (2003). Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 43:84–91
- Lee SA, Kim YM, Kwak TK, et al. (2009). The extracellular loop 2 of TM4SF5 inhibits integrin alpha2 on hepatocytes under collagen type I environment. Carcinogenesis 30:1872–9
- Lee SA, Lee MS, Ryu HW, et al. (2011). Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib. Cancer Biol Ther 11:330–6
- Li XQ, Bjorkman A, Andersson TB, et al. (2003). Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59:429–42
- Liu KH, Kim MG, Lee DJ, et al. (2006). Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos 34:1793–7
- Mancy A, Dijols S, Poli S, et al. (1996). Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry 35:16205–12
- Rodrigues AD. (1999). Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465–80
- Seo WD, Ryu YB, Curtis-Long MJ, et al. (2010). Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem, 45:2010–17
- Suzuki H, Kneller MB, Haining RL, et al. (2002). (+)-N-3-Benzyl-nirvanol and (−)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metab Dispos 30:235–9
- Walsky RL, Obach RS, Gaman EA, et al. (2005). Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413–18
- Wu S, Moomaw CR, Tomer KB, et al. (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460–8